885521-60-8 Usage
General Description
3-BROMO-4-FLUORO (1H)INDAZOLE is a chemical compound with the molecular formula C8H5BrFN2. It is a heterocyclic aromatic compound that contains both bromine and fluorine atoms. 3-BROMO-4-FLUORO (1H)INDAZOLE is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is known for its potential use as a building block in the production of various biologically active molecules, making it a valuable compound in the field of medicinal and organic chemistry. Its unique structure and reactivity make it a versatile and important chemical in the field of chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 885521-60-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,5,2 and 1 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 885521-60:
(8*8)+(7*8)+(6*5)+(5*5)+(4*2)+(3*1)+(2*6)+(1*0)=198
198 % 10 = 8
So 885521-60-8 is a valid CAS Registry Number.
885521-60-8Relevant articles and documents
3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
-
Paragraph 0267, (2015/07/15)
The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
-
Page/Page column 45, (2014/03/22)
The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
-
Page/Page column 42, (2014/03/22)
The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
